ABVC BIOPHARMA, INC. (ABVC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | 389,276 | 117,142 |
| Cost of revenues | - | - | 296 | 190 |
| Gross loss | - | - | 388,980 | 116,952 |
| Stock-based compensation | 1,571,613 | 48,773 | - | 412,741 |
| Selling, general and administrative expenses | 690,094 | 615,371 | 301,208 | 640,451 |
| Research and development expenses | 33,276 | 28,861 | 37,825 | 40,401 |
| Total operating expenses | 2,294,983 | 693,005 | 339,033 | 1,093,593 |
| Loss from operations | -2,294,983 | -693,005 | 49,947 | -976,641 |
| Equity securities, fv-ni, gain (loss) | - | - | - | -79,057 |
| Operating sublease income | - | 12,000 | - | 478 |
| Other income (expenses) | -7,180 | 1,500 | 16,864 | 22,193 |
| Interest income | 19,139 | 19,071 | 44,261 | 27,141 |
| Interest expense | 129,413 | 222,967 | 219,533 | 260,032 |
| Loss on investment in equity securities | -44,917 | -50,877 | -67,885 | - |
| Gain (loss) on foreign exchange | 136,148 | -9,912 | 30,429 | -117,665 |
| Operating sublease income | 12,000 | - | 12,000 | - |
| Total other expenses | -14,223 | -251,185 | -183,864 | -406,942 |
| Loss before provision income tax | -2,309,206 | -944,190 | -133,917 | -1,383,583 |
| Provision for income tax expense | 23,627 | - | 355 | -110,894 |
| Net loss | -2,332,833 | -944,190 | -134,272 | -1,272,689 |
| Net loss attributable to noncontrolling interests | -75,811 | -102,115 | 52,289 | -260,044 |
| Net loss attributed to abvc and subsidiaries | -2,257,022 | -842,075 | -186,561 | - |
| Foreign currency translation adjustment | 39,640 | -1,493 | 25,389 | 202,569 |
| Net income (loss) available to common stockholders, basic | - | - | - | -1,012,645 |
| Comprehensive loss | -2,217,382 | -843,568 | -161,172 | -810,076 |
| Basic (in dollars per share) | -0.13 | -0.06 | -0.02 | -0.09 |
| Diluted (in dollars per share) | -0.13 | -0.06 | -0.02 | -0.09 |
| Weighted average number of common shares outstanding, basic (in shares) | 17,386,536 | 14,968,232 | 12,405,261 | 11,321,277 |
| Weighted average number of common shares outstanding, diluted (in shares) | 17,386,536 | 14,968,232 | 12,405,261 | 11,321,277 |